Long-Term (=5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.
Long-Term (=5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2025 Jun 03; JCO2500760.
PMID: 40459151
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood Adv. 2025 May 07.
PMID: 40334078
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2025 May; 26(5):596-608.
PMID: 40220771
Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma.
Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma. Blood Cancer J. 2025 Mar 28; 15(1):47.
PMID: 40155599
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System.
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System. J Appl Lab Med. 2025 Mar 03; 10(2):235-249.
PMID: 39699179
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma.
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma. Blood Neoplasia. 2025 Feb; 2(1):100065.
PMID: 40454405
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System.
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System. J Appl Lab Med. 2024 Dec 19.
PMID: 39699179
Germline predisposition in multiple myeloma.
Germline predisposition in multiple myeloma. iScience. 2025 Jan 17; 28(1):111620.
PMID: 39845416
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma. Future Oncol. 2025 Jan; 21(1):25-49.
PMID: 39452950
Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma.
Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma. EJHaem. 2024 Dec; 5(6):1260-1264.
PMID: 39691273